MCF Advisors’s Dermata Therapeutics DRMA Stock Holding History

MCF Advisors’s Portfolio DRMA Stock Details DRMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.23K	Hold	1,732	–	–	﹤0.01%	1258
2026 Q1	$2.1K	Buy	+1,732	New	+$2.92K	﹤0.01%	1194

Other funds holding DRMA

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Advisory Alpha Holland, Michigan $4.08B AUM 20.62% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

MCF Advisors's DRMA Position: Q2 2026 in Review

MCF Advisors held its Dermata Therapeutics (DRMA) position steady in Q2 2026 at 1,732 shares worth $2.23K. The position accounts for ﹤0.01% of the portfolio, ranked #1258.

MCF Advisors first reported a position in DRMA in Q1 2026 and has held it in 2 quarters since. 13 funds tracked by Wall St. Rank hold DRMA as of Q2 2026.

MCF Advisors held 1,732 shares of Dermata Therapeutics worth $2.23K as of Q2 2026.
MCF Advisors left its Dermata Therapeutics share count unchanged in Q2 2026.
Dermata Therapeutics made up ﹤0.01% of MCF Advisors's portfolio in Q2 2026, its #1258 holding.
MCF Advisors first reported a position in Dermata Therapeutics in Q1 2026 and has held it in 2 quarters since.
13 funds tracked by Wall St. Rank held Dermata Therapeutics as of Q2 2026.

Based on MCF Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.